{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(1)"],"submitter":["Selmani Z"],"pubmed_abstract":["Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2- early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures the expression of 21 specific genes from tumor tissue, including Ki67. The primary aim of this study was to assess the agreement between Ki67<sub>RNA</sub> obtained with Oncotype DX RS and Ki67<sub>IHC</sub>. Other objectives were to analyze the association between the event free survival (EFS) and the expression level of Ki67<sub>RNA</sub>; and association between RS and Ki67<sub>RNA</sub>. Herein, we report a low agreement of 0.288 by Pearson correlation coefficient test between Ki67<sub>IHC</sub> and Ki67<sub>RNA</sub> in a cohort of 98 patients with early ER+/HER2- breast cancers. Moreover, Ki67<sub>RNA</sub><sup>high</sup> tumors were significantly associated with the occurrence of events (p = 0.03). On the other hand, we did not find any association between Ki67<sub>IHC</sub> and EFS (p = 0.26). We observed a low agreement between expression level of Ki67<sub>RNA</sub> and Ki67 protein labelling by IHC. Unlike Ki67<sub>IHC</sub> and independently of the RS, Ki67<sub>RNA</sub> could have a prognostic value. It would be interesting to better assess the prognosis and predictive value of Ki67<sub>RNA</sub> measured by qRT-PCR. The Ki67<sub>RNA</sub> in medical routine could be a good support in countries where Oncotype DX is not accessible."],"journal":["Scientific reports"],"pagination":["3617"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8901910"],"repository":["biostudies-literature"],"pubmed_title":["Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry."],"pmcid":["PMC8901910"],"pubmed_authors":["Curtit E","Dobi E","Feugeas JP","Meneveau N","Bazan F","Pivot X","Overs A","Selmani Z","Meynard G","Algros MP","Molimard C","Borg C","Mansi L","Paillard MJ","Pretet JL","Viot J","Chaigneau L"],"additional_accession":[]},"is_claimable":false,"name":"Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry.","description":"Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2- early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures the expression of 21 specific genes from tumor tissue, including Ki67. The primary aim of this study was to assess the agreement between Ki67<sub>RNA</sub> obtained with Oncotype DX RS and Ki67<sub>IHC</sub>. Other objectives were to analyze the association between the event free survival (EFS) and the expression level of Ki67<sub>RNA</sub>; and association between RS and Ki67<sub>RNA</sub>. Herein, we report a low agreement of 0.288 by Pearson correlation coefficient test between Ki67<sub>IHC</sub> and Ki67<sub>RNA</sub> in a cohort of 98 patients with early ER+/HER2- breast cancers. Moreover, Ki67<sub>RNA</sub><sup>high</sup> tumors were significantly associated with the occurrence of events (p = 0.03). On the other hand, we did not find any association between Ki67<sub>IHC</sub> and EFS (p = 0.26). We observed a low agreement between expression level of Ki67<sub>RNA</sub> and Ki67 protein labelling by IHC. Unlike Ki67<sub>IHC</sub> and independently of the RS, Ki67<sub>RNA</sub> could have a prognostic value. It would be interesting to better assess the prognosis and predictive value of Ki67<sub>RNA</sub> measured by qRT-PCR. The Ki67<sub>RNA</sub> in medical routine could be a good support in countries where Oncotype DX is not accessible.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T20:50:09.606Z","creation":"2025-04-04T20:50:09.606Z"},"accession":"S-EPMC8901910","cross_references":{"pubmed":["35256657"],"doi":["10.1038/s41598-022-07593-7"]}}